Eukaryotic cells are used as cell factories to produce and secrete multitudes of recombinant pharmaceutical proteins, including several of the current top-selling drugs. Due to the essential role and complexity of the secretory pathway, improvement for recombinant protein production through metabolic engineering has traditionally been relatively ad-hoc; and a more systematic approach is required to generate novel design principles. Here, we present the proteome-constrained genome-scale protein secretory model of yeast Saccharomyces cerevisiae (pcSecYeast), which enables us to simulate and explain phenotypes caused by limited secretory capacity. We further apply the pcSecYeast model to predict overexpression targets for the production of several recombinant proteins. We experimentally validate many of the predicted targets for α-amylase production to demonstrate pcSecYeast application as a computational tool in guiding yeast engineering and improving recombinant protein production.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9142503 | PMC |
| http://dx.doi.org/10.1038/s41467-022-30689-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Construction of Immune Single Domain Antibodies Library for Development of Specific Nanobodies Using Phage Display Strategy.
Recent Pat Biotechnol
January 2025
Center of Excellence in Recombinant Biopharmaceutical Proteins, Biochemistry and Molecular Biology Department, Theodor Bilharz Research Institute, Giza, Egypt.
Background: poses a considerable global public health challenge. In Egypt, approximately 60% of the inhabitants in the Northern and Eastern areas of the Nile Delta are affected by this parasite, whereas the Southern region experiences a significantly lower infection rate of 6%.
Aim: Construction of an immune phage display Nbs library based on the VHH framework for selecting -specific Nbs for seeking cost-effective, sensitive, and specific diagnostic tools for rapidly detecting mansoni.
Virus-like particle: a nano-platform that delivers cancer antigens to elicit an anti-tumor immune response.
Front Immunol
January 2025
School of Medicine, Wuhan University of Science and Technology, Wuhan, Hubei, China.
Virus-like particles (VLPs), as a unique form of nanocarrier, predominantly encompass hollow protein shells that exhibit analogous morphology and structure to naturally occurring viruses, yet devoid of genetic material. VLPs are considered safe, easily modifiable, and stable, making them suitable for preparation in various expression systems. They serve as precise biological instruments with broad applications in the field of medical biology.
View Article and Find Full Text PDFDevelopment of nucleic acid-based vaccines against dengue and other mosquito-borne flaviviruses: the past, present, and future.
Front Immunol
January 2025
Infectious Disease Research Department, King Abdullah International Medical Research Center, King Saud bin Abdulaziz University of Health Sciences, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia.
Due to their widespread geographic distribution and frequent outbreaks, mosquito-borne flaviviruses, such as DENV (DENV), Zika virus (ZIKV), Japanese encephalitis virus (JEV), yellow fever virus (YFV), and West Nile virus (WNV), are considered significant global public health threats and contribute to dramatic socioeconomic imbalances worldwide. The global prevalence of these viruses is largely driven by extensive international travels and ecological disruptions that create favorable conditions for the breeding of and species, the mosquito vectors responsible for the spread of these pathogens. Currently, vaccines are available for only DENV, YFV, and JEV, but these face several challenges, including safety concerns, lengthy production processes, and logistical difficulties in distribution, especially in resource-limited regions, highlighting the urgent need for innovative vaccine approaches.
View Article and Find Full Text PDFAssessment of heat-killed expressing Chikungunya virus E2 protein as a candidate vaccine for dual protection against Chikungunya virus and .
Front Immunol
January 2025
Nanobioscience Group, Agharkar Research Institute, Pune, India.
The Chikungunya virus (CHIKV) is a mosquito-borne virus with a long history of recurring epidemics transmitted through mosquitoes. The rapid spread of CHIKV has intensified the need for potent vaccines. Escherichia coli (), a vital part of human gut microbiota, is utilized in recombinant DNA technology for cloning.
View Article and Find Full Text PDFC-X-C chemokine receptor type 5CD8 T cells as immune regulators in hepatitis Be antigen-positive chronic hepatitis B under interferon-alpha treatment.
World J Gastroenterol
January 2025
Institute of Hepatology and Department of Infectious Diseases, The Second Xiangya Hospital, Central South University, Changsha 410011, Hunan Province, China.
Background: C-X-C chemokine receptor type 5 (CXCR5)CD8 T cells represent a unique immune subset with dual roles, functioning as cytotoxic cells in persistent viral infections while promoting B cell responses. Despite their importance, the specific role of CXCR5CD8 T cells in chronic hepatitis B (CHB), particularly during interferon-alpha (IFN-α) treatment, is not fully understood. This study aims to elucidate the relationship between CXCR5CD8 T cells and sustained serologic response (SR) in patients undergoing 48 weeks of pegylated IFN-α (peg-IFN-α) treatment for CHB.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!